The aim – to analyze the effect of two different schemes of anesthesia on early cardiac complications in patients with coronary artery bypass grafting (CABG) with cardiopulmonary bypass.Materials and methods. The study included 120 patients who underwent CABG with cardiopulmonary bypass (CPB). The median surgery risk according to EuroSCORE II was 3.45 % (2.15 %; 4.05 %). According to the scheme of anesthesia, all patients were divided into two groups: the first group (60 patients) – low-opioid scheme of anesthesia; the second group (60 patients) – a standard scheme of anesthesia.Results. Patients in the first group were more than twice as likely to develop postoperative atrial fibrillation compared to the second group (9 (15.0 %) vs. 19 (31.7 %), p = 0.031). In addition, patients in the first group were 2.3 times significantly less likely to have low cardiac output syndrome (LCOS) compared to the second group (11.7 % vs. 26.7 %, p = 0.037). The duration of CPB (p = 0.032) and the level of interleukin-6 after CPB (p = 0.004) were reliable indicators for predicting LCOS. The final statistical model [F (4, N = 120) = 12.52, p < 0.001, R2 = 0.304] covers almost a third of all factors in the development of LCOS. Only the level of interleukin-6 after CPB (the final statistical model (F (4, N = 120) = 11.54, p < 0.001, R2 = 0.286) was a reliable indicator for predicting postoperative atrial fibrillation.Conclusions. The obtained results confirm the safety of clinical use of anesthesia schemes with low doses of opioids in cardiac surgery patients and emphasize the possibility of a more conservative use of opioids in cardiac surgery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.